We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Biomarker Test Could Confirm Long COVID Diagnosis

By LabMedica International staff writers
Posted on 12 Aug 2025

Long COVID remains a diagnostic challenge, with clinicians currently relying on a collection of symptoms that appear 12 weeks or more after SARS-CoV-2 infection. More...

No blood tests or biomarkers currently exist to confirm the condition, leaving diagnosis largely presumptive. Now, a new study has uncovered a possible biological signal that could serve as the first specific, quantifiable indicator for the condition.

Researchers from the Translational Genomics Research Institute (TGen, Phoenix, AZ, USA;) have identified SARS-CoV-2 protein fragments within extracellular vesicles (EVs) in the blood of long COVID patients. EVs are tiny, naturally occurring packages that transport proteins, metabolites, and other materials between cells.

The study, reported in Infection, analyzed 56 blood samples from 14 patients over 12 weeks of aerobic exercise training in a long COVID clinical trial. Researchers found 65 distinct protein fragments from the virus’s Pp1ab protein, an RNA replicase enzyme essential for viral replication. This protein is unique to SARS-CoV-2 and not found in uninfected human cells.

Significantly, these viral peptides were demonstrated in each long COVID patient, though not in every sample taken, and were not detected in a separate control group of pre-pandemic EV samples. Their presence supports growing evidence that SARS-CoV-2 may persist in certain tissues long after acute infection. Some scientists suggest lingering viral reservoirs could contribute to the ongoing symptoms of long COVID.

The findings raise key questions about the nature of these peptides—whether they indicate ongoing viral replication or are merely residual “molecular trash” left after viral protein formation. The team has yet to test individuals without long COVID symptoms who have been infected with SARS-CoV-2, leaving the broader significance of the biomarker to be determined.

"This raises the question: is this just continuing to take out the trash from the COVID-infected cell or is this really ongoing replication someplace? I think that’s the mechanistic issue that needs to be resolved in future studies," said William Stringer, M.D., Lundquist Institute investigator and senior author of the study.

Related Links:
TGen


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette
Accumax Smart Series
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies (Photo courtesy of Salgia NJ et al., Cancer Cell, 2025)

Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers

Sarcomatoid renal cell carcinoma (sRCC) is a rare, aggressive form of kidney cancer comprising about 5% of cases and is typically diagnosed at late stages. Resistant to most therapies, it has shown unusually... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.